Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

On World Anti-Corruption Day, Ipsen re-affirms its commitment to the principles of the United Nations Global Compact Program

Always the innovator, Ipsen introduces social responsibility to its external funding conditions

Ipsen in Oncology: Mo’tivated for Movember and beyond

Ipsen in Oncology: Unlocking the power of data